Sleep Disorders

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 10, 2020.

The Director of the Sleep Disorders Center and vice chair of the department of neurology at the UCLA David Geffen School of Medicine detailed how patients and physicians can be proactive in identifying narcolepsy.

As a marker of impending neurodegeneration, urgency surrounds efforts to slow or stop the progression of REM sleep behavior disorder.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 3, 2020.

NeurologyLive’s parent company, MJH Life Sciences, will be hosting the virtual MJH Life Sciences Sleeves Up Blood Drive from March 31 through April 30.

The executive vice president of research and development at Jazz Pharmaceuticals discussed what the clinical community needs to know ahead of the regulatory decision on JZP-258 in the treatment of cataplexy and excessive daytime sleepiness in narcolepsy.

New data suggest that brain changes in the posterior cingulate cortex and precuneus as a result of SDB may increase the risk of Alzheimer disease, supporting prior findings which imply a link between the conditions.

Pear Therapeutics’ Somryst intervention provides tailored neurobehavioral interventions intended to improve the symptoms of insomnia, via cognitive behavioral therapy and algorithm-driven sleep restriction.

The novel oxybate agent is seeking an indication for the treatment of cataplexy and excessive daytime sleepiness in those 7 years and older with narcolepsy. The PDUFA date is July 21, 2020.

The director of the Sleep Disorders Center and vice chair of the department of neurology at the UCLA David Geffen School of Medicine detailed the comorbidities related to narcolepsy.

The webinar, a partnership between Women Neurologist's Group (WNG) and NeurologyLive, features the latest updates from CMS on billing and coding for telemedicine visits.